Not yet recruiting
Squamous cell carcinoma of the oral cavity+1
Not yet recruitingStudy of neoadjuvant intratumoral ipilimumab combined with systemic nivolumab in patients with locally advanced resectable oral cavity squamous cell carcinoma
Registered drugNo placebo
Study of neoadjuvant intratumoral ipilimumab combined with systemic nivolumab in patients with locally advanced resectable oral cavity squamous cell carcinoma
Registered drugNo placebo
- Disease:Squamous cell carcinoma of the oral cavityLip and/or oral cavity cancer
- Substances:IpilimumabNivolumab
Countries:
The Netherlands
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Ipilimumab
- Sponsor:Amsterdam UMC Stichting